RA190Small Molecule Proteasome Inhibitor for Cancer Therapy

Targeting the proteasome…

• Proteasomal degradation of tumor suppressor proteins is found in many cancers

• apoptosis arrest

• sustained cell proliferation

•RA190:

• Reduced toxicity

• novel mechanism of action overcomes drug resistance

• Preferential targeting of transformed cells

• Current proteasome inhibitors:

– grave side effects

– disease resistance

Mechanism Of Action

• Binds to ubiquitin receptor RPN13

• RPN13 is part of the 19S Regulatory Cap• Responsible for removing Ub from target

proteins

• Proteasome inhibited• Misfolded protein buildup

The Drug• Orally available

• Promising toxicity profile

• Works on tumors resistant to bortezumib

• Active against cervical and ovarian cancer, and Multiple Myeloma

The Business

What we do: Find cancer cure

Who we are: CanCure Inc.“Because we CanCure cancer*!”

* By cancer, we mean cervical and ovarian cancer, and multiple myeloma.

The Team• Looking to build a highly dedicated, talented, and

experienced management team:

• Looking for:• CEO: preferably with product launch experience• CFO• CMO• CRO• VPs• Etc…

The Market• Ovarian cancer: 17th most common cancer

• 21,980 estimated new cases in 2014• 14,270 deaths

• Cervical cancer: 21st most common cancer• 12,360 estimated new cases in 2014

• 4,020 deaths

• Multiple myeloma: 14th most common cancer• 24,050 estimated new cases in 2014

• 11,090 deaths

*From NCI SEER statistics 2014

Financial Projections

1 2 3 4 50

200

400

600

800

1000

1200

218.96

437.93

656.89

875.85

1,094.81

109.48

218.96

328.44

437.93

547.41

Revenue

Profits

Years on Market

Do

lla

rs (

Mil

lio

ns

)

Growth Strategy

• Develop companion diagnostic test for RA190

• Explore RA190 in other cancers

Exit Strategy• Sell company to large pharma